Antigen-MHC Nanoparticle Complexes for Targeted MS Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for multiple sclerosis (MS) are often poorly tolerated and ineffective, with a need for better-tolerated and more effective therapies that can address the autoimmune nature of the disease without compromising systemic immunity.
Innovation Solution
Administration of antigen-MHC-nanoparticle complexes, specifically designed to expand and develop populations of anti-pathogenic autoreactive T-cells by targeting multiple sclerosis-related antigens, which are delivered using biocompatible nanoparticles to modulate the immune response and reduce disease severity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current MS treatments are administered, then disease symptoms may be suppressed, but the treatments are poorly tolerated and have adverse effects
Solution Approach 1:
The treatment is segmented into multiple specific antigen targets (MOG35-55, MBP83-99, PLP138-151, MAG142-154) rather than using broad immunosuppression. Each antigen-specific T-cell population is expanded and regulated independently, allowing targeted intervention that spares overall immune function and reduces adverse effects.
Solution Approach 2:
The treatment applies local quality by targeting specific autoreactive T-cell populations with distinct antigen specificities rather than applying uniform immunosuppression throughout the immune system. This localized approach regulates pathogenic T-cells while preserving systemic immunity and reducing treatment-related harm.
2Reliability
If broad immunosuppression is used to treat MS, then disease activity may be reduced, but systemic immunity is compromised
Solution Approach 1:
The therapy segments the immune response by targeting four distinct antigen-specific T-cell populations rather than suppressing the entire immune system. This allows disease control through regulation of pathogenic T-cells while maintaining adaptive immunity against pathogens and preserving immune versatility.
Solution Approach 2:
Autoregulatory T-cells serve as intermediaries that specifically suppress pathogenic autoreactive T-cells without affecting overall immune function. These regulatory T-cells mediate localized suppression of disease-causing cells while preserving systemic immune adaptability and response to external threats.
3Reliability
If antigen-specific T-cell expansion is performed, then anti-pathogenic autoreactive T-cells are increased, but treatment complexity increases
Solution Approach 1:
Multiple antigen-specific T-cell expansions are merged into a single comprehensive therapy protocol. The four antigen-specific approaches (MOG35-55, MBP83-99, PLP138-151, MAG142-154) are combined to simultaneously target multiple pathogenic T-cell populations, achieving comprehensive disease control through an integrated treatment strategy.
Solution Approach 2:
The treatment methodology is made universal by establishing a standardized protocol that can be applied to multiple different antigen-specific T-cell populations. The same expansion and regulation approach is used across all four antigen targets, creating a multi-functional therapy that addresses diverse pathogenic T-cell populations through a unified method.
Data Source
AI summary
This disclosure provides therapeutic compositions and methods for treating multiple sclerosis or a multiple sclerosis-related disorder in a subject in need thereof comprising administering an effective amount of an antigen-MHC-nanoparticle complex to the subject, wherein the antigen is a multiple sclerosis-related antigen.